180 related articles for article (PubMed ID: 37393758)
21. Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
Regnery S; Eichkorn T; Weykamp F; Held T; Weusthof K; Dinges LA; El-Shafie RA; Winter H; Thomas M; Debus J; Adeberg S; Hörner-Rieber J
Clin Lung Cancer; 2021 Jul; 22(4):332-340.e3. PubMed ID: 33281061
[TBL] [Abstract][Full Text] [Related]
22. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.
Haseltine JM; Rimner A; Gelblum DY; Modh A; Rosenzweig KE; Jackson A; Yorke ED; Wu AJ
Pract Radiat Oncol; 2016; 6(2):e27-33. PubMed ID: 26577006
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Moderate-Intensity Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumor.
Rim CH; Yoon WS; Park S
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674184
[No Abstract] [Full Text] [Related]
25. Stereotactic body radiotherapy for de novo spinal metastases: systematic review.
Husain ZA; Sahgal A; De Salles A; Funaro M; Glover J; Hayashi M; Hiraoka M; Levivier M; Ma L; Martínez-Alvarez R; Paddick JI; Régis J; Slotman BJ; Ryu S
J Neurosurg Spine; 2017 Sep; 27(3):295-302. PubMed ID: 28598293
[TBL] [Abstract][Full Text] [Related]
26. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Radiosurgery for Postoperative Spine Malignancy: A Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.
Faruqi S; Chen H; Fariselli L; Levivier M; Ma L; Paddick I; Pollock BE; Regis J; Sheehan J; Suh J; Yomo S; Sahgal A
Pract Radiat Oncol; 2022; 12(2):e65-e78. PubMed ID: 34673275
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors.
Zhao Y; Khawandanh E; Thomas S; Zhang S; Dunne EM; Liu M; Schellenberg D
Radiat Oncol; 2020 Feb; 15(1):61. PubMed ID: 32106868
[TBL] [Abstract][Full Text] [Related]
29. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
[TBL] [Abstract][Full Text] [Related]
32. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
33. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
Park HS; Harder EM; Mancini BR; Decker RH
J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
[TBL] [Abstract][Full Text] [Related]
34. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis.
Yu T; Shin IS; Yoon WS; Rim CH
Clin Lung Cancer; 2019 Jul; 20(4):e452-e462. PubMed ID: 31029573
[TBL] [Abstract][Full Text] [Related]
36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
37. A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations.
Alongi F; Nicosia L; Figlia V; De Sanctis V; Mazzola R; Giaj-Levra N; Reverberi C; Valeriani M; Osti MF
Clin Transl Oncol; 2021 Oct; 23(10):2133-2140. PubMed ID: 33840047
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach : A prospective observational study.
Mazzola R; Ruggieri R; Figlia V; Rigo M; Giaj Levra N; Ricchetti F; Nicosia L; Corradini S; Alongi F
Strahlenther Onkol; 2019 Aug; 195(8):719-724. PubMed ID: 30689026
[TBL] [Abstract][Full Text] [Related]
39. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
40. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
